Chronic Hepatitis B
The Chronic Hepatitis B pipeline: 34 tracked drugs, 7 approved for this indication.
7 approved / phase 45 Phase 39 Phase 26 Phase 1/26 Phase 11 preclinical / unstaged
Compare the share prices of listed companies in Chronic Hepatitis B →
Total attributable cost
$20.0B
$11,773/patient
Drug spend
Not yet sourced
any · US